Article: Chronic kidney disease: Statins in chronic kidney disease: time to move on?

Statins reduce the risk of atherosclerotic vascular disease in healthy individuals and those with chronic kidney disease (CKD); however, clinical trials have suggested a minimal effect of statins on CKD progression. The PLANET trials compared the renal effects of rosuvastatin and atorvastatin, but the findings leave many questions unanswered.

Citing Articles

Effect of selenium supplementation on hemodialysis patients: a meta-analysis.

Cheng Q, Fan D, Chen P, Yuan H Int Urol Nephrol. 2025; .

PMID: 39900786 DOI: 10.1007/s11255-025-04400-w.

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin.

Kroonen M, Stevens J, de Zeeuw D, Heerspink H Diabetes Obes Metab. 2019; 21(12):2635-2642.

PMID: 31414562 PMC: 6900110. DOI: 10.1111/dom.13849.

Diabetic nephropathy: Time to withhold development and progression - A review.

Sharaf El Din U, Salem M, Abdulazim D J Adv Res. 2017; 8(4):363-373.

PMID: 28540086 PMC: 5430158. DOI: 10.1016/j.jare.2017.04.004.

Stop chronic kidney disease progression: Time is approaching.

Sharaf El Din U, Salem M, Abdulazim D World J Nephrol. 2016; 5(3):258-73.

PMID: 27152262 PMC: 4848149. DOI: 10.5527/wjn.v5.i3.258.

References

1.

Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A . Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014; 25(8):1825-33. PMC: 4116066. DOI: 10.1681/ASN.2013090965. View

2.

Wanner C, Tonelli M . KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014; 85(6):1303-9. DOI: 10.1038/ki.2014.31. View

3.

Sidaway J, Davidson R, McTaggart F, Orton T, Scott R, Smith G . Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol. 2004; 15(9):2258-65. DOI: 10.1097/01.ASN.0000138236.82706.EE. View

4.

Moorhead J, Chan M, El-Nahas M, Varghese Z . Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982; 2(8311):1309-11. DOI: 10.1016/s0140-6736(82)91513-6. View

5.

de Zeeuw D, Anzalone D, Cain V, Cressman M, Lambers Heerspink H, Molitoris B . Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015; 3(3):181-90. DOI: 10.1016/S2213-8587(14)70246-3. View

6.

Jacobson T . Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol. 2006; 97(8A):44C-51C. DOI: 10.1016/j.amjcard.2005.12.009. View

7.

Baigent C, Blackwell L, Emberson J, Holland L, Reith C, Bhala N . Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753):1670-81. PMC: 2988224. DOI: 10.1016/S0140-6736(10)61350-5. View

8.

Stone N, Robinson J, Lichtenstein A, Merz C, Blum C, Eckel R . 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 129(25 Suppl 2):S1-45. DOI: 10.1161/01.cir.0000437738.63853.7a. View

9.

Baigent C, Landray M, Reith C, Emberson J, Wheeler D, Tomson C . The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377(9784):2181-92. PMC: 3145073. DOI: 10.1016/S0140-6736(11)60739-3. View

10.

Colantonio L, Baber U, Banach M, Tanner R, Warnock D, Gutierrez O . Contrasting Cholesterol Management Guidelines for Adults with CKD. J Am Soc Nephrol. 2014; 26(5):1173-80. PMC: 4413767. DOI: 10.1681/ASN.2014040400. View

Chronic Kidney Disease: Statins in Chronic Kidney Disease: Time to Move On?